NXLNexalin Technology, Inc.vs its industry peers
A metric-by-metric comparison of Nexalin Technology, Inc. against Electromedical & Electrotherapeutic Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NXL본 종목 | $112M#8 | — | 74.0x#15 | 372.6x#14 | 78.8%#3 | -8.1%#8 | -2781.7%#14 | -541.1%#14 | — | — | -79.0%#15 | — |
| AXGN | $2.4B#1 | — | 9.3x#10 | 10.6x#10 | 20.2%#9 | -57.6%#12 | -3.5%#3 | -6.1%#5 | -4.8%#3 | 4#5 | 155.8%#3 | — |
| BLFS | $1.8B#2 | 31.1x#4 | 4.3x#7 | 18.6x#11 | 28.9%#6 | 77.2%#1 | -17.3%#5 | -1.1%#4 | — | 6#1 | 39.5%#7 | — |
| CNMD | $1.4B#3 | 24.5x#3 | 1.3x#3 | 1.0x#3 | 5.2%#13 | -64.4%#13 | 7.5%#2 | 4.5%#3 | 3.8%#2 | 5#4 | -10.1%#10 | 1.8%#1 |
| CBLL | $937M#4 | — | 7.3x#9 | 10.5x#9 | 36.1%#4 | -32.0%#11 | -65.6%#10 | -41.6%#7 | — | — | 94.0%#5 | — |
| CV | $334M#5 | 2.1x#1 | 25.4x#14 | 24.6x#12 | 15.3%#10 | -27.2%#10 | -188.3%#12 | -192.3%#12 | — | — | 40.8%#6 | — |
| ELMD | $221M#6 | 20.3x#2 | 4.1x#6 | 3.0x#6 | 15.3%#11 | 49.9%#3 | 18.8%#1 | 20.9%#2 | 31.5%#1 | 6#1 | 8.9%#8 | — |
| STXS | $132M#7 | — | 10.8x#11 | 4.1x#8 | 20.3%#8 | 10.0%#6 | -68.3%#11 | -176.8%#11 | -1081.1%#8 | 4#5 | -53.0%#13 | — |
| VANI | $108M#9 | — | 5.7x#8 | — | — | 13.3%#5 | — | 140.3%#1 | -2164.7%#9 | — | -19.3%#11 | — |
| ECOR | $105M#10 | — | — | 3.3x#7 | 27.2%#7 | -17.5%#9 | -41.1%#8 | — | — | — | 136.1%#4 | — |
| NRXS | $95M#11 | — | 14.1x#12 | 26.6x#13 | 32.9%#5 | 5.4%#7 | -219.4%#13 | -115.8%#9 | — | — | 190.6%#2 | — |
| STEX | $73M#12 | — | 0.5x#1 | 1812.8x#15 | 122.2%#2 | -4379.9%#16 | -177735.0%#15 | -317.8%#13 | — | — | -90.2%#16 | — |
| OM | $59M#13 | — | 0.6x#2 | 0.5x#2 | 5.1%#14 | 36.2%#4 | -55.8%#9 | -84.8%#8 | -40.7%#4 | 4#5 | -77.9%#14 | — |
| POCI | $47M#14 | — | 2.3x#4 | 2.5x#5 | -0.1%#15 | -95.8%#14 | -29.1%#7 | -28.7%#6 | -51.1%#5 | 3#8 | 2.6%#9 | — |
| QTI | $37M#15 | — | 16.7x#13 | 2.0x#4 | 287.9%#1 | -134.6%#15 | -23.4%#6 | -938.7%#15 | -163.2%#7 | 6#1 | 287.9%#1 | — |
| IRIX | $12M#16 | — | 3.2x#5 | 0.2x#1 | 8.2%#12 | 50.2%#2 | -4.9%#4 | -121.9%#10 | -155.0%#6 | 3#8 | -48.7%#12 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3845). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-19.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice